{"anticipatedPostingDate":"2027-05","denomUnitsSelected":"Participants","reportingStatus":"NOT_POSTED","timeFrame":"From randomization up to 30 days after last dose of study treatment or disease progression or initiation of subsequent therapy, whichever occurs first (up to 3 years)","title":"Percentage of Participants Who Achieved Overall MRD (at 10^-5) Negativity Conversion From Baseline to End of Study Treatment Period","type":"SECONDARY"}